
ADvantage Therapeutics
ADvantage Therapeutics develops novel therapeutics to treat neurodegenerative conditions, with a major focus on Alzheimer’s Disease.
- 9
- Company
- Miami, FL, USUnited States

ADvantage Therapeutics develops novel therapeutics to treat neurodegenerative conditions, with a major focus on Alzheimer’s Disease.
advantagetherapeutics.comCrawled Oct 15, 2026
AAIC24_Poster_template v5
ADvantage Therapeutics, Inc. announced that the first patient was enrolled in its European Phase 2b clinical trial of AD04 for mild Alzheimer’s disease.
Advantage Therapeutics Inc. announced the formation of its subsidiary, KlotheaBio, Inc. Klothea Bio secured funding from Longevitytech.fund as a lead investor.
ADvantage Therapeutics announced that Dr. Kuro-o would speak at the Second Annual Entrepreneurship, Longevity and Biotech Conference and announced an appointment to its Scientific Advisory Board.
ADvantage Therapeutics Inc. 195 NW 40th Street Miami, FL 33127 Email: office@advantagetherapeutics.com
The company is developing an immunotherapy for early AD.
ADvantage Therapeutics Inc.’s privacy policy describes how it collects, uses, maintains, and discloses information from visitors to its website and linked online services.
Klothea begins recruiting participants for a **Phase 1 human trial** of its **klotho mRNA therapy**, targeting longevity. The trial takes place in a **special economic zone on Roatán**, a Caribbean island. The company aims to assess safety and preliminary efficacy in humans.
Feb 2026Longevity.TechnologyNews article
Klothea Bio initiates a Phase 1b clinical trial testing **AKL003**, its experimental alpha Klotho mRNA therapy, in healthy adult volunteers. The study is randomized, double-blind, and placebo-controlled, with recruitment underway at **GARM Clinic** in Prospera, Roatan, Honduras. This marks the company’s first human evaluation of the investigational treatment.
Feb 2026packgeneNews article
Klothea Bio initiates a Phase 1b clinical trial for **AKL003**, an mRNA-based therapy designed to activate the **alpha klotho protein** in humans. The trial aims to investigate the therapeutic’s potential to extend lifespan by targeting aging-related biological pathways. This follows earlier research linking alpha klotho to longevity and cellular protection.
Feb 2026GlobeNewswire News RoomNews article
Dr. Mark Hyman has joined ADvantage Therapeutics’ advisory board to support the development of Klotho-based longevity therapies through its subsidiary, Klothea Bio. The move aims to accelerate research and clinical progress in anti-aging treatments targeting the Klotho protein, a key regulator of aging processes. ADvantage Therapeutics focuses on leveraging this protein to extend healthspan and address age-related diseases.
Oct 2025GlobeNewswire News RoomNews article